🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Co-Chairs of the Alliance for Clinical Trials in Oncology Breast Committee - Lisa Carey, MD, ScM, FASCO UNC Lineberger & Ann Partridge MD, MPH Dana-Farber will present "Progress from the Alliance Breast Committee: Assessing and Addressing Unmet Needs" at the 2025 Alliance Spring Plenary Session. #NCI #AllianceSpring25

Only 2 weeks to #ESMOBreast25, one of my favorite conferences. Dozens of impactful abstracts to be presented, alongside great educational presentations to put the new data into context. Here’s a personal selection of 10 key presentations to follow during the conference. #bcsm

Premature discontinuation of adjuvant ET is common in early breast cancer - Ann Partridge MD, MPH and I discuss the study by Dumas et al. modelling the potential survival benefits of improved ET persistence, particularly for young adults with breast cancer 🔗doi.org/10.1200/JCO-25…

Ei è Non più immobile #5Maggio

Check out this recent Annals of Oncology #ctDNA review and meta-analysis👉Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors. 👉pubmed.ncbi.nlm.nih.gov/40187491/

Casper Ruud con una delle conferenze stampa più belle della storia: "Sì, bisogna riconoscerlo: da avversario in campo è la prestazione più vicina alla perfezione che abbia mai visto. Voglio dire, nei primi 4 game forse ho fatto un paio di gratuiti, cercando di andare per il

In her Keynote Lecture, Ann Partridge MD, MPH discusses recent progress in the treatment of young women with #BreastCancer, considering some of the unique needs and challenges, and key initiatives such as the BCY session at #ESMOBreast25 #ESMODailyReporter 🔗 ow.ly/15IC50VTY7Y

❤️❤️

15-year follow-up from SOFT & TEXT trials! Premenopausal HR+ early #BreastCancer patients benefit from OFS + AI combo Here’s what we learned: DFS ➡️ T: 67.0% ➡️ T+OFS: 70.5% ➡️ E+OFS: 73.5% DRFI ➡️ T: 85.3% ➡️ T+OFS: 86.7% ➡️ E+OFS: 86.9% OS ➡️ T: 85.3% ➡️ T+OFS: 86.7% ➡️ E+OFS:

Are the data so compelling that first-line is vastly better than 2nd line? And the other question is: how adequate or appropriate is the cross-over therapy? Because the ethical standard would be to include cross-over.

“We shall not cease from exploration And the end of all our exploring Will be to arrive where we started And know the place for the first time”. (T. S. Eliot) MPH in Clinical Effectiveness Harvard T.H. Chan School of Public Health

Ready for the Harvard University Commencement with Harold J. Burstein, MD, PhD, FASCO!!

VERITAC-2 published in NEJM Vepdegestrant ⬆️ mPFS from 2 to 5m but only in ESR1mut. No benefit at all in ESR1 wt nejm.org/doi/full/10.10…

Important to see OS benefit. A theme for ASCO #ASCO25 is vital need of defining X-over therapy/therapy at PD. In INAVO120, crossover was variable; 85% chemo but only 35% got ADC, 5% got PIK3CA inhibitor, 39% more ET. Likely important for SERANA-6 and DB-09 trials, too.

❤️🔥

Data for the oral taxane, DHP107, were pretty compelling. Looks the 'same' as IV paclitaxel; met all non-inferiority criteria, and K-M curves pass the eyeball test. It would be terrific to have an oral paclitaxel option for patients.

Grateful for a terrific year at Dana-Farber’s Breast Oncology Center under the mentorship of Ann Partridge MD, MPH ❤️🔥 Guilherme Nader Marta

#ASCO25 #plenary If the graph on the left is practice changing, the graph on the right is urgently practice changing. Cost to health systems-$15K to $18K a month vs $100-$150 a month. ATOMIC trial vs CHALLENGE trial.

Wonderful and clear discussion on the real impact of SERENA6 on our patients’ trajectory Angie DeMichele, MD, MSCE, FASCO, Thank you!! ASCO

❤️